Memantine

Generic Name
Memantine
Brand Names
Axura, Ebixa, Marixino, Namenda, Namenda 49 Titration Pack, Namzaric, Nemdatine, Memantine Mylan, Memantine ratiopharm, Memantine Merz, Marixino (previously Maruxa), Memantine Accord, Memantine LEK
Drug Type
Small Molecule
Chemical Formula
C12H21N
CAS Number
19982-08-2
Unique Ingredient Identifier
W8O17SJF3T
Background

Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease . ...

Indication

Memantine is used to manage moderate to severe Alzheimer's dementia .
...

Associated Conditions
Alzheimer's Disease (AD), Moderate to Severe Alzheimer's Disease, Mild Vascular dementia, Moderate Alzheimer's Type Dementia, Moderate Vascular dementia, Severe Alzheimer's Type Dementia
Associated Therapies
-
Clinical Trials
Related News

Memantine Augmentation of Lamotrigine Incomplete-Response in Bipolar Depression

Phase 4
Completed
Conditions
Bipolar Depression
Interventions
Drug: Placebo
Drug: Memantine
First Posted Date
2006-03-22
Last Posted Date
2016-07-18
Lead Sponsor
Indiana University School of Medicine
Target Recruit Count
29
Registration Number
NCT00305578
Locations
🇺🇸

Indiana University Adult Psychiatric Clinic, Indianapolis, Indiana, United States

Namenda to Prevent Post-Operative Delirium

Phase 4
Terminated
Conditions
Delirium
Post-Operative States
First Posted Date
2006-03-16
Last Posted Date
2015-06-03
Lead Sponsor
University of Rochester
Target Recruit Count
30
Registration Number
NCT00303433
Locations
🇺🇸

University of Rochester Medical Center, Rochester, New York, United States

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

Phase 2
Completed
Conditions
Multiple Sclerosis
Cognition Disorders
First Posted Date
2006-03-09
Last Posted Date
2019-10-15
Lead Sponsor
Oregon Health and Science University
Target Recruit Count
82
Registration Number
NCT00300716
Locations
🇺🇸

OHSU, Portland, Oregon, United States

🇺🇸

USC, Los Angeles, California, United States

🇺🇸

MS Hub, Seattle, Washington, United States

and more 1 locations

Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia

First Posted Date
2006-02-22
Last Posted Date
2017-09-12
Lead Sponsor
Johns Hopkins University
Target Recruit Count
20
Registration Number
NCT00294554
Locations
🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes

Phase 4
Terminated
Conditions
Mood
Memory Deficit
Interventions
Drug: Memantine
Drug: Riluzole
First Posted Date
2006-01-27
Last Posted Date
2013-04-23
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
20
Registration Number
NCT00283309
Locations
🇺🇸

UT Southwestern, Dallas, Texas, United States

Memantine for Corticosteroid-Induced Mood and Declarative Memory Changes

Phase 4
Completed
Conditions
Physiological Effects of Drugs
First Posted Date
2006-01-23
Last Posted Date
2008-01-25
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
20
Registration Number
NCT00280774
Locations
🇺🇸

Parkland Health and Hospital System (Asthma, Allergy, & Arthritis Clinics), Dallas, Texas, United States

Memantine Augmentation in Obsessive-Compulsive Disorder

Phase 1
Completed
Conditions
Obsessive-Compulsive Disorder
Interventions
Drug: Memantine
First Posted Date
2005-12-12
Last Posted Date
2017-05-30
Lead Sponsor
Stanford University
Target Recruit Count
15
Registration Number
NCT00264238
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Treatment of Orthostatic Intolerance

First Posted Date
2005-12-06
Last Posted Date
2024-10-02
Lead Sponsor
Satish R. Raj
Target Recruit Count
150
Registration Number
NCT00262470
Locations
🇺🇸

Vanderbilt University Autonomic Dysfunction Center, Nashville, Tennessee, United States

The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients

Phase 3
Completed
Conditions
Alzheimer Disease
Interventions
Drug: Placebo pill
Drug: Memantine
First Posted Date
2005-11-17
Last Posted Date
2017-04-07
Lead Sponsor
Stanford University
Target Recruit Count
17
Registration Number
NCT00255086
Locations
🇺🇸

VA Palo Alto Health Care System, Palo Alto, California, United States

A Placebo-Controlled Trial of Memantine for Alcohol Dependence

First Posted Date
2005-10-30
Last Posted Date
2008-10-08
Lead Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Target Recruit Count
90
Registration Number
NCT00246415
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy